Beyfortus Market Report 2026

Beyfortus Market Report 2026
Epidemiology, Pipeline Analysis, Market Insights & Forecasts
Beyfortus Market Overview
• The Beyfortus market growth in the historic period has been driven by high rsv hospitalization rates in infants, unmet need for rsv prevention • Market expansion is supported by expanding newborn protection programs, increasing rsv awareness • Growth Driver: Rising RSV Cases Driving Market Growth For Beyfortus • Market Trend: Advancements In Antibody-Based Treatments For RSV Prevention And Efficacy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Beyfortus Market?
Beyfortus refers to a monoclonal antibody medication (nirsevimab) designed to provide passive immunity against respiratory syncytial virus (RSV). It is used for the prevention of RSV lower respiratory tract infections in newborns and infants during their first RSV season, offering long-lasting protection with a single dose. The main indications for beyfortus are RSV prevention and infant care. RSV prevention refers to measures aimed at protecting infants from Respiratory Syncytial Virus (RSV), a leading cause of severe respiratory illness in young children. It is distributed through various channels, including hospitals, pharmacies, and public health programs.
What Is The Beyfortus Market Size and Share 2026?
The growth in the historic period can be attributed to high rsv hospitalization rates in infants, unmet need for rsv prevention, monoclonal antibody advancements, neonatal care improvements, regulatory approvals.What Is The Beyfortus Market Growth Forecast?
The growth in the forecast period can be attributed to expanding newborn protection programs, increasing rsv awareness, public health funding growth, broader clinical guidelines adoption, long acting antibody innovation. Major trends in the forecast period include rising adoption of passive immunization, focus on rsv prevention in infants, single dose long acting antibody use, hospital based neonatal protection programs, seasonal rsv preparedness strategies.Global Beyfortus Market Segmentation
1) By Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Care 2) By Age Group: Infants And Neonates, Children, Elderly Population 3) By Distribution Channel: Hospitals, Pharmacies, Public Health ProgramsWhat Are The Drivers Of The Beyfortus Market?
The increasing incidence of RSV cases is expected to propel the growth of the beyfortus market going forward. Respiratory syncytial virus (RSV) is a highly contagious virus that primarily infects the respiratory tract, causing illnesses such as bronchiolitis and pneumonia, especially in infants, young children, older adults, and immunocompromised individuals. The increasing incidence of RSV cases is largely driven by reduced population immunity. Beyfortus enhances respiratory health management by providing targeted protection against RSV, making it ideal for infants, older adults, and immunocompromised individuals. It reduces the risk of severe RSV infections, improving overall patient safety and public health outcomes. For instance, In March 2025, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, approximately 3.6 million hospitalizations and around 100,000 deaths occur due to RSV each year among children under 5 years of age each year. Therefore, the increasing incidence of RSV cases is driving the growth of the Beyfortus industry. The increasing research and development activities are expected to propel the growth of the beyfortus market going forward. Research and development activities involve the systematic exploration and development of new knowledge, products, or technologies through research and experimentation. Research and development activities are increasing due to the growing demand for innovative solutions to address emerging health threats and improve treatment efficacy. Research and development activities enhance Beyfortus by driving innovations in RSV prevention, making it more effective for high-risk populations. They improve safety and efficacy profiles, supporting broader adoption and better patient outcomes. For instance, in July 2025, according to Eurostat, a Luxembourg-based statistical agency, the total government budget allocations for research and development across the EU reached an estimated €127,916 million in 2024, marking a 3.4% increase compared with €123,675 million in 2023. Therefore, the increasing research and development activities is driving the growth of the beyfortus industry.Key Players In The Global Beyfortus Market
Major companies operating in the beyfortus market are AstraZeneca plc, Sanofi SAGlobal Beyfortus Market Trends and Insights
Major companies operating in the beyfortus market are focusing on developing advanced therapies, such as monoclonal antibodies, to combat widespread health threats and improve patient outcomes. Monoclonal antibodies refer to laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens by precisely targeting them. For instance, in July 2023, Sanofi SA, a France-based healthcare company, partnered with AstraZeneca Plc, a UK-based pharmaceutical and biotechnology company, and granted marketing authorization from the European Commission for beyfortus (nirsevimab). It is a single-dose, long-acting monoclonal antibody designed for the prevention of Respiratory Syncytial Virus (RSV) in newborns and infants. It works by providing direct immunity against RSV, offering immediate protection for the duration of the RSV season.Regional Insights
North America was the largest region in the beyfortus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.What Defines the Beyfortus Market?
The beyfortus market consists of sales of vaccines, allergy and over-the-counter medications, oncology drugs and central nervous system drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Beyfortus Market Report 2026?
The beyfortus market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the beyfortus industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Beyfortus Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $ billion |
| Revenue Forecast In 2035 | $ billion |
| Growth Rate | No CAGR found from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Indication, Age Group, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | AstraZeneca plc, Sanofi SA |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
Frequently Asked Questions
The Beyfortus market was valued at $ billion in 2025, increased to $ billion in 2026, and is projected to reach $ billion by 2030.
The global Beyfortus market is expected to grow at a CAGR of nan% from 2026 to 2035 to reach $ billion by 2035.
Some Key Players in the Beyfortus market Include, AstraZeneca plc, Sanofi SA .
Major trend in this market includes: Advancements In Antibody-Based Treatments For RSV Prevention And Efficacy. For further insights on this market.
Request for SampleNorth America was the largest region in the beyfortus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the beyfortus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
